Exploring how melanoma cells resist treatment with specific drugs
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
This study is looking into why some melanoma patients initially do well with targeted treatments but then have their cancer come back, focusing on the tiny groups of cells that either resist the treatment from the beginning or learn to survive it; the researchers hope to find new ways to help these patients stay healthy longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10747860 on NIH RePORTER |
What this research studies
This research investigates why many patients with BRAFV600E/K melanoma initially respond to targeted therapies but eventually relapse. It focuses on understanding the behavior of small populations of melanoma cells that are either resistant to treatment from the start or adapt quickly to survive. By using advanced techniques like single-cell RNA analysis and barcoding, the study aims to track these resistant cells in both laboratory and animal models. The goal is to uncover new therapeutic strategies that could prevent or overcome drug resistance in melanoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with BRAFV600E/K melanoma who are undergoing treatment with BRAF/MEK inhibitors.
Not a fit: Patients with melanoma that does not carry the BRAFV600E/K mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients by overcoming drug resistance.
How similar studies have performed: Previous research has shown promise in understanding drug resistance in cancer, but this specific approach to studying BRAFV600E/K melanoma is novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Raj, Arjun — University of Pennsylvania
- Study coordinator: Raj, Arjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.